Federal

Cardiac Cases Raise Concerns Over Drugs for ADHD

By Christina A. Samuels — February 21, 2006 4 min read

Dr. Steven E. Nissen said he had no preconceived notions about drugs for attention deficit hyperactivity disorder when he was asked by the U.S. Food and Drug Administration to serve on a panel charged with creating protocols for testing such drugs.

But during a presentation, Dr. Nissen and other panel members learned of 25 reports of deaths between 1999 and 2003. Several dozen other cases of cardiovascular problems among users were reported in that period, many among people with pre-existing cardiac problems.

Dr. Nissen, a Cleveland cardiologist, felt he had enough information to take action. He suggested that stimulant medications for ADHD carry a prominent warning to pediatricians, a sign that doctors should take extra care before prescribing them.

Other panel members agreed. It voted 8-7 on Feb. 9 to recommend the warning labels for some ADHD medications. The warning does not prevent doctors from prescribing medications, but is intended to ensure that doctors know that their patients truly need the drugs and are aware of the risks.

The panel’s recommendation has reverberated around the country among doctors, parents of children who have been diagnosed with the disorder, and educators.

That’s just what Dr. Nissen, the interim director of cardiovascular medicine at the Cleveland Clinic, a renowned medical facility, wanted to happen.

“I want a public dialogue between parents and teachers and doctors,” he said in an interview last week. “People deserve to know what risks they’re taking with their medications.”

A Backlash

But the panel’s recommendation has also stirred a backlash, especially from psychiatrists and family physicians who prescribe medications for ADHD. They say the FDA advisory panel overstepped its charge and is making recommendations without knowing all the facts.

“It doesn’t astonish me that they wanted to weigh in,” Dr. Robert Temple, the director of the FDA’s office of medical policy, said at a press conference called after the panel’s decision. “But it wasn’t the primary matter we wanted them to weigh in on.”

The agency is not required to accept the panel’s recommendation, but officials said they would consider it.

“Every medication has a side effect,” said Dr. Lynn Wegner, a Morrisville, N.C., pediatrician who is the chairwoman of the section on developmental and behavioral pediatrics for the American Academy of Pediatrics. “The question is whether the risk is worth the reward.”

Dr. Wegner supports more study to determine whether people who have died after taking ADHD medications may have had underlying cardiac conditions. Before that’s known, it’s impossible to say just how harmful ADHD drugs may be to a wider population, she said.

Drugs Under Scrutiny

Psychostimulants are the most widely used medications for the treatment of attention deficit hyperactivity disorder. In 2003, 2.5 million children ages 4 to 17 were receiving such medications for the disorder, according to the federal Centers for Disease Control and Prevention.

A federal Food and Drug Administration advisory panel has recommended that psychostimulants carry a prominent warning that they may cause sudden death or have serious complications.

Medication Brand Names
methylphenidate Ritalin
Concerta
Metadate
Focalin
amphetamines Adderall
Dexedrine
Dextrostat

SOURCES: U.S. Food and Drug Administration; National Resource Center on AD/HD

But she envisions that some doctors may just throw up their hands and stop prescribing the medications to avoid legal liability. When the news of the panel’s recommendations came out, Dr. Wegner said she had 20 messages on her answering machine within days from parents and patients who wanted to talk to her about them.

“The general pediatrician who’s busy and reads this article in The New York Times may say, ‘I don’t want to do this anymore,’ ” she said.

According to the U.S. Centers for Disease Control and Prevention, located in Atlanta, 2.5 million U.S. children ages 4 to 17 were receiving medication for ADHD, a condition characterized by inattention and impulsivity, in 2003. Psychostimulant medications, sold under brand names such as Ritalin, Concerta, and Adderall, are most often prescribed to treat the disorder. Many of the drugs have been around for decades; Ritalin was approved by the FDA in 1955.

According to the CDC, 4.4 million U.S. 4- to 17-year-olds have been diagnosed with ADHD by a health-care professional. In 2003, 7.8 percent of school-age children were reported to have an ADHD diagnosis by their parent. IMS Health, a Fairfield, Conn.-based pharmaceutical-information and -consulting company, said ADHD medications accounted for $3.6 billion in sales last year.

Benefits Ignored?

The medications have come under fire before, from those who say they are overprescribed and have unknown side effects. In February 2005, Canadian health authorities removed Adderall from the market over concerns about sudden deaths, but they allowed the drug to be sold six months later, in August.

Shire Pharmaceuticals, the British company that manufactures Adderall, released a statement saying that the FDA panel’s action was “unwarranted.”

Adderall “already include[s] a black-box warning in their labels for safety concerns related to amphetamine abuse or misuse,” the statement added. “The label also warns of the risk of sudden death in patients with structural cardiac abnormalities.”

Also being overlooked, the statement from Shire said, are the benefits of the medication.

Ginny Thiersch, a spokeswoman for the Landover, Md.-based group Children and Adults with Attention Deficit/Hyperactivity Disorder, or CHADD, said that the FDA panel “put the recommendation before the science.”

Now, she said, parents may be prompted to take their children off the medication without talking to their doctors, a step that Ms. Thiersch believes could have disastrous effects on such children’s classroom behavior.

Dr. Nissen, one of the first physicians to sound an alarm about Vioxx, a pain medication pulled from the market after being linked to sudden cardiac deaths, said that it’s safer for consumers to have the warnings in place, and then allow the drug companies to determine whether the warnings were unwarranted.

He said he believes that ADHD drugs are overprescribed, sometimes at the request of teachers or school administrators. Many children do benefit from ADHD drugs, he said.

“But giving it to kids with marginal symptoms, as opposed to counseling them or working with them,” Dr. Nissen said, “may not be the right thing to do.”

Related Tags:

A version of this article appeared in the February 22, 2006 edition of Education Week as Cardiac Cases Raise Concerns Over Drugs for ADHD

Events

Student Well-Being Webinar Boosting Teacher and Student Motivation During the Pandemic: What It Takes
Join Alyson Klein and her expert guests for practical tips and discussion on how to keep students and teachers motivated as the pandemic drags on.
This content is provided by our sponsor. It is not written by and does not necessarily reflect the views of Education Week's editorial staff.
Sponsor
Student Well-Being Webinar
A Holistic Approach to Social-Emotional Learning
Register to learn about the components and benefits of holistically implemented SEL.
Content provided by Committee for Children
This content is provided by our sponsor. It is not written by and does not necessarily reflect the views of Education Week's editorial staff.
Sponsor
Student Well-Being Webinar
How Principals Can Support Student Well-Being During COVID
Join this webinar for tips on how to support and prioritize student health and well-being during COVID.
Content provided by Unruly Studios

EdWeek Top School Jobs

Interdisciplinary STEAM Specialist
Smyrna, Georgia
St. Benedict's Episcopal School
Interdisciplinary STEAM Specialist
Smyrna, Georgia
St. Benedict's Episcopal School
Arizona School Data Analyst - (AZVA)
Arizona, United States
K12 Inc.
Software Engineer
Portland, OR, US
Northwest Evaluation Association

Read Next

Federal Biden Legal Team Steps Back From Trump Stance on Transgender Female Sports Participation
The Education Department's office for civil rights pulls a letter that said Connecticut's transgender-inclusive policy violates Title IX.
4 min read
Bloomfield High School transgender athlete Terry Miller, second from left, wins the final of the 55-meter dash over transgender athlete Andraya Yearwood, far left, and other runners in the Connecticut girls Class S indoor track meet at Hillhouse High School in New Haven, Conn on Feb. 7, 2019. Transgender athletes are getting an ally in the White House next week as they seek to participate as their identified gender in high school and college sports. Attorneys on both sides say they expect President-elect Joe Biden’s Department of Education will switch sides in legal battles that could go a long way in determining whether transgender athletes are treated by the sex on their birth certificates or by how they identify.
Bloomfield High School transgender athlete Terry Miller, second from left, wins over transgender athlete Andraya Yearwood, far left, and other runners in an event in New Haven, Conn. The two transgender athletes are at the center of a legal fight in Connecticut over the participation of transgender female athletes in girls' or women's sports.
Pat Eaton-Robb/AP
Federal Congress Again Tries to Pass Eagles Act, Focused on School Shootings After Parkland
A group of bipartisan Congressional lawmakers is once again trying to get a law passed aimed at preventing school violence.
Devoun Cetoute & Carli Teproff
2 min read
Suzanne Devine Clark, an art teacher at Deerfield Beach Elementary School, places painted stones at a memorial outside Marjory Stoneman Douglas High School on Feb. 14, 2019 during the first anniversary of the school shooting in Parkland, Fla.
Suzanne Devine Clark, an art teacher at Deerfield Beach Elementary School, places painted stones at a memorial outside Marjory Stoneman Douglas High School on Feb. 14, 2019 during the first anniversary of the school shooting in Parkland, Fla.
Wilfredo Lee/AP
Federal Some Districts Extend Paid Leave Policies as They Hope for Passage of Biden Relief Plan
With federal provisions having expired, some school employees have had to dip into their own banks of leave for COVID-19 purposes.
5 min read
Linda Davila-Macal, a seventh grade reading teacher at BL Garza Middle School in Edinburg, Texas, works from her virtual classroom at her home on Aug. 31, 2020.
A teacher leads a virtual classroom from her home.
Delcia Lopez/The Monitor via AP
Federal President Biden Is Walking a 'Careful Tightrope' When It Comes to School Reopenings
CDC guidance and confusion over his rhetoric turn up the pressure, and could overshadow progress in schools and nuanced public opinion.
9 min read
President Joe Biden answers questions during a televised town hall event at Pabst Theater in Milwaukee on Feb. 16, 2021.
President Joe Biden answers questions during a televised town hall event in Milwaukee earlier this month.
Evan Vucci/AP